Banyan Corp. (BNYN) Stock

About Banyan Corp.

Banyan Corp., operating through its subsidiaries, focuses on franchising chiropractic clinics throughout North America. The company provides extensive support to its franchisees and licensees, including specialized practice development training and assistance tailored for chiropractors. Beyond its franchising activities, Banyan delivers vital diagnostic testing services. A key offering is Nerve Conduction Velocity (NCV) testing, which is administered to patients via healthcare professionals such as doctors and chiropractors. This NCV testing is instrumental in evaluating the transmission of nerve impulses, identifying irregularities within the nervous system, and supplying objective data to substantiate treatment expenses for patients and their insurance providers. Furthermore, Banyan manufactures and markets its proprietary VT3000, an advanced nerve testing system. This system is engineered for the precise diagnosis of neuropathies – conditions affecting the peripheral nerves and spinal regions – alongside nerve irritation and other forms of nervous system damage in patients. Established in 1978, Banyan Corp. maintains its headquarters in Beverly Hills, California.

Banyan Corp. (BNYN) stock trades at $0.00 with a market capitalization of $286042. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.00, price-to-sales of 0.06. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.

On profitability, Banyan Corp. generates return on capital employed of -65.97%, an operating margin of -27.01%, a net profit margin of -114.99%.

Official website: www.banyancorp.com